CA3084137A1 - Cancer vaccines targeting lemd1 and uses thereof - Google Patents

Cancer vaccines targeting lemd1 and uses thereof Download PDF

Info

Publication number
CA3084137A1
CA3084137A1 CA3084137A CA3084137A CA3084137A1 CA 3084137 A1 CA3084137 A1 CA 3084137A1 CA 3084137 A CA3084137 A CA 3084137A CA 3084137 A CA3084137 A CA 3084137A CA 3084137 A1 CA3084137 A1 CA 3084137A1
Authority
CA
Canada
Prior art keywords
seq
nucleic acid
amino acid
acid sequence
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3084137A
Other languages
English (en)
French (fr)
Inventor
Jian Yan
Anna SLAGER
Bradley GARMAN
Neil COOCH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inovio Pharmaceuticals Inc
Original Assignee
Inovio Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inovio Pharmaceuticals Inc filed Critical Inovio Pharmaceuticals Inc
Publication of CA3084137A1 publication Critical patent/CA3084137A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3084137A 2017-12-13 2018-12-13 Cancer vaccines targeting lemd1 and uses thereof Pending CA3084137A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762598329P 2017-12-13 2017-12-13
US62/598,329 2017-12-13
US201762598612P 2017-12-14 2017-12-14
US62/598,612 2017-12-14
PCT/US2018/065534 WO2019118771A1 (en) 2017-12-13 2018-12-13 Cancer vaccines targeting lemd1 and uses thereof

Publications (1)

Publication Number Publication Date
CA3084137A1 true CA3084137A1 (en) 2019-06-20

Family

ID=66734873

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3084137A Pending CA3084137A1 (en) 2017-12-13 2018-12-13 Cancer vaccines targeting lemd1 and uses thereof

Country Status (11)

Country Link
US (2) US11338028B2 (https=)
EP (1) EP3724217A4 (https=)
JP (3) JP7314139B2 (https=)
KR (2) KR20240096711A (https=)
CN (1) CN111479822A (https=)
AU (2) AU2018384824B2 (https=)
BR (1) BR112020011620A2 (https=)
CA (1) CA3084137A1 (https=)
MX (2) MX2020006305A (https=)
RU (1) RU2760984C1 (https=)
WO (1) WO2019118771A1 (https=)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1487877B1 (en) 2001-09-18 2010-10-27 Genentech, Inc. Compositions and methods for the diagnosis of tumors
WO2004021010A2 (en) * 2002-08-30 2004-03-11 Oncotherapy Science, Inc. Method of diagnosing colon and gastric cancers
EP1954826A4 (en) 2005-11-27 2010-05-05 Compugen Ltd NEW NUCLEOTIDE AND AMINO ACID SEQUENCES AND TESTS AND METHOD FOR THEIR USE FOR DIAGNOSIS
DK2091965T3 (da) 2006-10-17 2013-08-05 Oncotherapy Science Inc Peptidvacciner mod cancere, der udtrykker MPHOSPH1- eller DEPDC1-polypeptider
KR101174452B1 (ko) * 2009-05-11 2012-08-16 한국생명공학연구원 대장암 및 전이에 대한 바이오마커, 이를 이용한 대장암 진단 및 치료제 스크리닝
PL391627A1 (pl) * 2010-06-25 2012-01-02 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
JP2014525584A (ja) * 2011-08-31 2014-09-29 オンコサイト コーポレーション 癌の治療および診断のための方法および組成物
US20140315743A1 (en) * 2011-10-03 2014-10-23 Karen Chapman Methods and Compositions for the Treatment and Diagnosis of Ovarian Cancer
AU2013243948A1 (en) * 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
CA2888648C (en) * 2012-12-13 2021-06-08 The Trustees Of The University Of Pennsylvania Wt1 vaccine
WO2017203526A1 (en) * 2016-05-23 2017-11-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of diagnosing cancer using cancer testis antigens

Also Published As

Publication number Publication date
US11338028B2 (en) 2022-05-24
EP3724217A1 (en) 2020-10-21
KR20200096959A (ko) 2020-08-14
AU2018384824B2 (en) 2022-08-04
AU2018384824A8 (en) 2020-07-30
CN111479822A (zh) 2020-07-31
AU2022263546A1 (en) 2022-12-08
US20190175712A1 (en) 2019-06-13
JP2025065334A (ja) 2025-04-17
RU2760984C1 (ru) 2021-12-02
EP3724217A4 (en) 2022-01-12
JP2023111915A (ja) 2023-08-10
US20220265800A1 (en) 2022-08-25
KR102673699B1 (ko) 2024-06-17
MX2024005404A (es) 2024-08-06
JP7633306B2 (ja) 2025-02-19
WO2019118771A1 (en) 2019-06-20
MX2020006305A (es) 2020-09-17
KR20240096711A (ko) 2024-06-26
BR112020011620A2 (pt) 2020-12-08
JP2021506264A (ja) 2021-02-22
JP7314139B2 (ja) 2023-07-25
AU2018384824A1 (en) 2020-07-16

Similar Documents

Publication Publication Date Title
US20220265801A1 (en) Cancer Vaccines Targeting PRAME and Uses Thereof
US20240358809A1 (en) Cancer vaccines targeting survivin and uses thereof
US12161706B2 (en) Cancer vaccines targeting BORIS and uses thereof
US11986517B2 (en) Cancer vaccines targeting mesothelin and uses thereof
JP7633306B2 (ja) Ｌｅｍｄ１を標的とするがんワクチンおよびその使用
WO2019118764A1 (en) Cancer vaccines targeting muc16 and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200601

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241122

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241122

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241122

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251127

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251201

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260205